# Efficacy and Safety of SYN-010 in IBS-C

> **NCT03763175** · PHASE2 · TERMINATED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 59 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Constipation

## Interventions

- **DRUG:** SYN-010 21 mg
- **DRUG:** SYN-010 42 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03763175
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-24
- **Primary completion:** 2020-10-09
- **Final completion:** 2020-10-09
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Interim Futility Analysis
- **Last updated:** 2022-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03763175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03763175, "Efficacy and Safety of SYN-010 in IBS-C". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03763175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*